Quotient Wealth Partners LLC Sells 535 Shares of AstraZeneca PLC $AZN

Quotient Wealth Partners LLC cut its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 12.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 3,616 shares of the company’s stock after selling 535 shares during the period. Quotient Wealth Partners LLC’s holdings in AstraZeneca were worth $253,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Goldman Sachs Group Inc. lifted its holdings in AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after acquiring an additional 3,224,251 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in AstraZeneca by 14,797.3% during the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock worth $162,306,000 after acquiring an additional 2,307,047 shares in the last quarter. American Century Companies Inc. lifted its holdings in AstraZeneca by 406.9% during the first quarter. American Century Companies Inc. now owns 2,020,629 shares of the company’s stock worth $148,517,000 after acquiring an additional 1,621,974 shares in the last quarter. Boston Partners lifted its holdings in AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company’s stock worth $368,712,000 after acquiring an additional 1,329,166 shares in the last quarter. Finally, Deutsche Bank AG lifted its holdings in shares of AstraZeneca by 650.1% in the first quarter. Deutsche Bank AG now owns 1,234,847 shares of the company’s stock valued at $90,761,000 after purchasing an additional 1,070,223 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AZN. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “hold” rating to a “sell” rating in a report on Thursday. Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.00.

AstraZeneca Price Performance

NASDAQ:AZN opened at $84.69 on Monday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. The stock’s 50-day simple moving average is $80.23 and its 200 day simple moving average is $73.86. The company has a market cap of $262.66 billion, a P/E ratio of 31.84, a P/E/G ratio of 1.56 and a beta of 0.36. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $86.57.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.AstraZeneca’s quarterly revenue was up 16.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.24 earnings per share. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, September 8th. Investors of record on Friday, August 8th were given a $0.505 dividend. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca’s payout ratio is currently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.